Stroke Trial, Recruiting NCT05531461 Sponsor: Rapid Medical Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT05531461
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been admitted to hospital with a blockage in a large blood vessel in the brain and are being treated with a device called the Tigertriever, according to its approved instructions for use.
  • People for whom the Tigertriever was used as the first treatment attempted in the affected blood vessel.
  • People who have provided signed informed consent to participate.
  • People aged between 18 and 75 years (inclusive).
  • People who had little to no disability before their stroke (a pre-stroke score of 0 or 1 on a standard disability scale).

Who may not be able to join:

  • People who had any other device used to clear the blocked vessel before the Tigertriever was used, including suction-based catheters.
  • People who showed signs of bleeding in the brain on a CT or MRI scan at the time of admission.
  • People who have had a brain bleed, stroke, clot-dissolving treatment, or a procedure to open blocked blood vessels within the past 3 months.
  • People with a suspected condition called cerebral amyloid angiopathy (a disease affecting blood vessels in the brain — confirm with trial site).
  • People who were diagnosed with dementia before their stroke, or who were taking a type of medication called cholinesterase inhibitors prior to their stroke.
  • People who were diagnosed with, or were being treated for, major depression before their stroke.
  • People who had a learning or intellectual disability before their stroke.
  • People who are not expected to be available for a follow-up assessment at 6 months after treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +972 72 2503331

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Rapid Medical
Registry
ClinicalTrials.gov
Start date
28 October 2024
Est. completion
1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Association between successful reperfusion* and cognitive benefit**

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov